Maintaining effective treatment in dementia: a case series on patients switched to rivastigmine

In the clinical management of Alzheimer's disease (AD), switching cholinesterase (ChE) inhibitors is becoming an increasingly common practice following non-response or safety/tolerability problems with an initial agent. Data from clinical studies has demonstrated that approximately half of all patients benefit from switching. In this paper, we present eight case studies from our own clinical experience of switching ChE inhibitors, and highlight some of the potential benefits associated with this practice.